Search

Your search keyword '"Mely, Laurent"' showing total 114 results

Search Constraints

Start Over You searched for: Author "Mely, Laurent" Remove constraint Author: "Mely, Laurent"
114 results on '"Mely, Laurent"'

Search Results

1. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study

3. Cystic fibrosis related diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicenter trial

4. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

5. Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.

6. Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis

9. Dépistage des anomalies de la tolérance au glucose et du diabète de mucoviscidose. Position de la Société française de la mucoviscidose (SFM), de la Société francophone du diabète (SFD) et de la Société française d’endocrinologie et diabétologie pédiatrique (SFEDP)

11. Cystic fibrosis related diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicenter trial

13. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

15. Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF)

16. Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis

18. Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

19. Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis

21. Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

23. Additional file 3: Table S2. of DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis

24. Additional file 2: Figure S2. of DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis

26. Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease

28. Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRare® cohort

31. DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis

32. Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis

33. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTRvariant: a real-world study

34. Physical activity promotion in French cystic fibrosis centers: capitalizing on experience.

36. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients

41. The 1-Minute Sit-to-Stand Test in Adults With Cystic Fibrosis: Correlations With Cardiopulmonary Exercise Test, 6-Minute Walk Test, and Quadriceps Strength.

47. Unusual Aspergillus species in patients with cystic fibrosis.

48. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis

49. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.

50. Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis.

Catalog

Books, media, physical & digital resources